Pages that link to "Q30439459"
Jump to navigation
Jump to search
The following pages link to Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study (Q30439459):
Displaying 50 items.
- Advanced soft-tissue sarcoma and treatment options: critical appraisal of trabectedin (Q26738346) (← links)
- Current Chemotherapy and Potential New Targets in Uterine Leiomyosarcoma (Q26767435) (← links)
- Efficacy and safety of pharmacological interventions in second- or later-line treatment of patients with advanced soft tissue sarcoma: a systematic review (Q26822530) (← links)
- Practice guidelines for management of uterine corpus cancer in Korea: a Korean Society of Gynecologic Oncology Consensus Statement (Q28069514) (← links)
- Management Strategies in Advanced Uterine Leiomyosarcoma: Focus on Trabectedin (Q28087771) (← links)
- Uterine leiomyosarcoma: Epidemiology, contemporary treatment strategies and the impact of uterine morcellation (Q30235911) (← links)
- The importance of treating by histological subtype in advanced soft tissue sarcoma (Q30240223) (← links)
- A Phase II evaluation of ixabepilone (IND #59699, NSC #710428) in the treatment of recurrent or persistent leiomyosarcoma of the uterus: an NRG Oncology/Gynecologic Oncology Group Study (Q30370631) (← links)
- The evolution of systemic therapy in sarcoma. (Q33274710) (← links)
- Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial (Q33379886) (← links)
- Sunitinib malate in the treatment of recurrent or persistent uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study (Q33386535) (← links)
- A phase II evaluation of weekly gemcitabine and docetaxel for second-line treatment of recurrent carcinosarcoma of the uterus: a gynecologic oncology group study (Q33389469) (← links)
- Phase II study of weekly docetaxel and fixed dose rate gemcitabine in patients with previously treated advanced soft tissue and bone sarcoma. (Q33397403) (← links)
- A phase II evaluation of trabectedin in the treatment of advanced, persistent, or recurrent uterine leiomyosarcoma: a gynecologic oncology group study (Q33397625) (← links)
- A retrospective study on combination therapy with ifosfamide, adriamycin and cisplatin for progressive or recurrent uterine sarcoma (Q33415973) (← links)
- Randomized phase III trial of gemcitabine plus docetaxel plus bevacizumab or placebo as first-line treatment for metastatic uterine leiomyosarcoma: an NRG Oncology/Gynecologic Oncology Group study (Q33420695) (← links)
- A phase 2 study of alisertib (MLN8237) in recurrent or persistent uterine leiomyosarcoma: An NRG Oncology/Gynecologic Oncology Group study 0231D. (Q33438485) (← links)
- Efficacy and safety of trabectedin or dacarbazine in patients with advanced uterine leiomyosarcoma after failure of anthracycline-based chemotherapy: Subgroup analysis of a phase 3, randomized clinical trial (Q33442984) (← links)
- Locally-advanced unresected uterine leiomyosarcoma with triple-modality treatment combining radiotherapy, chemotherapy and hyperthermia: A case report (Q33844215) (← links)
- Cost-effectiveness of pazopanib in advanced soft tissue sarcoma in the United kingdom (Q33850011) (← links)
- Prognostic factors and survival in patients treated surgically for recurrent metastatic uterine leiomyosarcoma (Q33876398) (← links)
- Histology-driven chemotherapy of soft-tissue sarcoma (Q34624326) (← links)
- Adjuvant therapy for high-grade, uterus-limited leiomyosarcoma: results of a phase 2 trial (SARC 005). (Q34647409) (← links)
- Recent advances in understanding and managing leiomyosarcomas (Q34670825) (← links)
- Chemotherapy (gemcitabine, docetaxel plus gemcitabine, doxorubicin, or trabectedin) in inoperable, locally advanced, recurrent, or metastatic uterine leiomyosarcoma: a clinical practice guideline (Q35025163) (← links)
- A comprehensive safety evaluation of trabectedin and drug-drug interactions of trabectedin-based combinations. (Q35246995) (← links)
- A phase II trial to assess the activity of gemcitabine and docetaxel as first line chemotherapy treatment in patients with unresectable leiomyosarcoma. (Q35616803) (← links)
- A phase II study single agent of aflibercept (VEGF Trap) in patients with recurrent or metastatic gynecologic carcinosarcomas and uterine leiomyosarcoma. A trial of the Princess Margaret Hospital, Chicago and California Cancer Phase II Consortia (Q35830911) (← links)
- Long-lasting activity of trabectedin in refractory uterine leiomyosarcoma: a case report (Q35875724) (← links)
- Flavokawain B, a novel, naturally occurring chalcone, exhibits robust apoptotic effects and induces G2/M arrest of a uterine leiomyosarcoma cell line (Q36117059) (← links)
- Systemic therapy for advanced soft tissue sarcomas: highlighting novel therapies and treatment approaches (Q36144210) (← links)
- Dual targeting of mTOR and aurora-A kinase for the treatment of uterine Leiomyosarcoma (Q36205257) (← links)
- Potential Therapeutic Targets in Uterine Sarcomas. (Q36245677) (← links)
- New drugs and combinations for the treatment of soft-tissue sarcoma: a review (Q36444369) (← links)
- An unusual case of pedunculated subserosal leiomyosarcoma of the uterus mimicking ovarian carcinoma (Q36560780) (← links)
- Gynecologic Cancer InterGroup (GCIG) consensus review: uterine and ovarian leiomyosarcomas (Q36795987) (← links)
- The role of adjuvant therapy in uterine leiomyosarcoma (Q36811788) (← links)
- A nomogram to predict postresection 5-year overall survival for patients with uterine leiomyosarcoma (Q36826881) (← links)
- Improved clinical trial enrollments for uterine leiomyosarcoma patients after gynecologic oncology partnership with a sarcoma center (Q36883521) (← links)
- Major clinical research advances in gynecologic cancer 2008 (Q37177750) (← links)
- Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. (Q37278365) (← links)
- A small-molecule inhibitor targeting the mitotic spindle checkpoint impairs the growth of uterine leiomyosarcoma (Q37296303) (← links)
- Uterine sarcoma 2008. (Q37301331) (← links)
- Malignant mixed müllerian tumor of primary peritoneal origin (Q37305469) (← links)
- Feasibility and efficacy of gemcitabine and docetaxel combination chemotherapy for bone and soft tissue sarcomas: multi-institutional retrospective analysis of 134 patients (Q37487765) (← links)
- Phase I study of gemcitabine, docetaxel and imatinib in refractory and relapsed solid tumors (Q37634058) (← links)
- Clinical management of uterine sarcomas (Q37643987) (← links)
- Role of chemotherapy in the management of soft tissue sarcomas (Q37687389) (← links)
- Histology-Driven Chemotherapy in Soft Tissue Sarcomas (Q37848174) (← links)
- Emerging therapeutic targets for soft tissue sarcoma (Q37869364) (← links)